Efficacy and safety of the novel α4β2 neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study
暂无分享,去创建一个
L. Adler | W. Abi-Saab | C. Kratochvil | M. Saltarelli | W. Robieson | Y. Pritchett | George G Apostol | D. Feifel | L. Gault | M. Collins